Kelly Manning
Staff Scientist
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Articles (8)
Background: Maternal immunization provides vaccine-specific immunity to the infant via breast milk. Multiple studies have reported the presence of SARS-CoV-2 antibodies in human breast milk (HBM) from infected and/or vaccinated women. However, there is limited information on the analytical performance, consistency, and quality of the methods used. Standardized and rigorous assays are needed to meet clinical study endpoints and for comparisons across studies. Methods: We optimized high-throughput multiplex immunoassays for quantification of SARS-CoV-2 immunoglobulin (Ig)G and IgA in HBM and determined antibody levels in HBM samples from 236 SARS-CoV-2 vaccinated (infected and non-infected) and 50 pre-pandemic (unexposed) lactating women. Additionally, SARS-CoV-2 neutralizing activity was examined in a subset of 75 SARS-CoV-2 HBM from vaccinated (infected and non-infected) women using live virus focus reduction neutralization and pseudovirus assays. Concordance between SARS-CoV-2 binding and live virus neutralization outcomes was examined. Results: The multiplex SARS-CoV-2 assays had adequate analytical sensitivity, repeatability, precision, and assay linearity and were reliable for quantification of IgG and IgA in HBM. Positivity thresholds for Spike- and Nucleocapsid-specific IgG and IgA were established; IgG discriminated positive/negative SARS-CoV-2-immune HBM with high sensitivity and specificity, while IgA reactivity overlapped. A strong correlation was observed between live SARS-CoV-2 and pseudovirus neutralization activity. HBM Spike IgA and neutralization titers were highly correlated. Conclusions: SARS-CoV-2 binding and neutralizing antibody activity in HBM was determined using standardized and rigorous assays. HBM positivity cutoff values for SARS-CoV-2 vaccination and infection were established. The methods and approach described here could be applied to other pathogens and mucosal secretions.
Year:
2025
Supplementary Table 2: Antibodies used for immune-phenotyping (CyTOF analysis). Supplementary Table 3: Antibodies used for flow cytometry. Supplementary Table 4: Antibodies used for AIM Assay (CyTOF analysis).
Year:
2025
Year:
2024
Year:
2024
Year:
2023
Year:
2023
Year:
2023
Year:
2023
Collaborators (21)
Rafi Ahmed
Emory University School of Medicine
Meagan Deming
Assistant Professor
University of Maryland Center for Vaccine Development
Flor Munoz
Associate Professor
Baylor College of Medicine
Jonathan Kaufman
Winship Cancer Institute of Emory University
Alberto Moreno
Emory University
Renee Julia Manalo
Emory University
Marcela F. Pasetti
University of Maryland School of Medicine
Barbra Richardson
Fred Hutchinson Cancer Research Center
Mehul S. Suthar
Emory University School of Medicine
Sagar Lonial
-
Colin Swenson
Associate Professor
Emory University
Craig Hofmeister
Professor
Emory University
Rafi Ahmed
Emory University School of Medicine
Bryan Berube
Seattle Children's Research Institute
Ajay K. Nooka
Professor
Emory University
Courtney Olson-Chen
Associate Professor
University of Rochester Medical Center
Nisha Joseph
Associate Professor
Winship Cancer Institute of Emory University
Madhav V. Dhodapkar
-
Alessandro Sette
Professor and Member
La Jolla Institute for Immunology
Kavita M. Dhodapkar
Emory University
Jeffrey Switchenko
Emory University
Make your next move.
Prepare your application
Review drafts before you send them.